Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Hye Ryun Kim, Suresh S. Ramalingam, Frances A. Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Chee Khoon Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A. Papadimitrakopoulou

New England Journal of Medicine, 2016

Chinese University of Hong Kong, Sun Yat-sen University Cancer Center, Army Medical University, Sun Yat-sen University, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Sungkyunkwan University, Samsung Medical Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Yonsei University, Cancer Institute (WIA), Winship Cancer Institute, Emory University, Princess Margaret Cancer Centre, Daping Hospital, Wakayama Medical University, The Netherlands Cancer Institute, St George Hospital, Goethe University Frankfurt, AstraZeneca (United Kingdom), The University of Texas MD Anderson Cancer Center

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

3276

Citations

View on Google Scholar

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back